{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:56:21Z","timestamp":1773809781115,"version":"3.50.1"},"reference-count":36,"publisher":"Medical Association of Nippon Medical School","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2023,4,25]]},"DOI":"10.1272\/jnms.jnms.2023_90-211","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T22:11:52Z","timestamp":1676931112000},"page":"210-219","source":"Crossref","is-referenced-by-count":3,"title":["Medical Needs of Adults with Down Syndrome Presenting at a Regional Medical and Rehabilitation Center in Japan"],"prefix":"10.1272","volume":"90","author":[{"given":"Yoko","family":"Kanbara","sequence":"first","affiliation":[{"name":"Research and Development of Institute for Human Life Science, Ochanomizu University"},{"name":"Department of Nursing, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisen","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Osako","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Research and Development of Institute for Human Life Science, Ochanomizu University"},{"name":"Department of Genetic Counseling, Graduate School of Humanities and Science, Ochanomizu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiko","family":"Miyake","sequence":"additional","affiliation":[{"name":"Research and Development of Institute for Human Life Science, Ochanomizu University"},{"name":"Department of Genetic Counseling, Graduate School of Humanities and Science, Ochanomizu University"},{"name":"Division of Clinical Genetics, Nippon Medical School Hospital"},{"name":"Department of Obstetrics and Gynecology, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bull MJ. Down syndrome. N Engl J Med. 2020 Jun;382 (24):2344-52.","DOI":"10.1056\/NEJMra1706537"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Presson AP, Partyka G, Jensen KM, et al. Current estimate of Down syndrome population prevalence in the United States. J Pediatr. 2013 Oct;163 (4):1163-8.","DOI":"10.1016\/j.jpeds.2013.06.013"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Glasson EJ, Sullivan SG, Hussain R, Petterson BA, Montgomery PD, Bittles AH. The changing survival profile of people with Down&apos;s syndrome: implications for genetic counselling. Clin Genet. 2002 Nov;62 (5):390-3.","DOI":"10.1034\/j.1399-0004.2002.620506.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bittles AH, Glasson EJ. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol. 2004 Apr;46 (4):282-6.","DOI":"10.1111\/j.1469-8749.2004.tb00483.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sasaki A, Sago H. Equipoise of recent estimated Down syndrome live births in Japan. Am J Med Genet A. 2019 Sep;179 (9):1815-9.","DOI":"10.1002\/ajmg.a.61298"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Motegi N, Morisaki N, Suto M, Tamai H, Mori R, Nakayama T. Secular trends in longevity among people with Down syndrome in Japan, 1995-2016. Pediatr Int. 2021 Jan;63 (1):94-101.","DOI":"10.1111\/ped.14354"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics. 2011 Aug;128 (2):393-406.","DOI":"10.1542\/peds.2011-1605"},{"key":"8","unstructured":"8. Henderson A, Lynch SA, Wilkinson S, Hunter M. Adults with Down&apos;s syndrome: the prevalence of complications and health care in the community. Br J Gen Pract. 2007 Jan;57 (534):50-5."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bittles AH, Bower C, Hussain R, Glasson EJ. The four ages of Down syndrome. Eur J Public Health. 2007 Apr;17 (2):221-5.","DOI":"10.1093\/eurpub\/ckl103"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Capone GT, Chicoine B, Bulova P, et al. Co-occurring medical conditions in adults with Down syndrome: a systematic review toward the development of health care guidelines. Am J Med Genet A. 2018 Jan;176 (1):116-33.","DOI":"10.1002\/ajmg.a.38512"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. van Allen MI, Fung J, Jurenka SB. Health care concerns and guidelines for adults with Down syndrome. Am J Med Genet. 1999 Jun;89 (2):100-10.","DOI":"10.1002\/(SICI)1096-8628(19990625)89:2<100::AID-AJMG8>3.0.CO;2-N"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Alexander M, Petri H, Ding Y, Wandel C, Khwaja O, Foskett N. Morbidity and medication in a large population of individuals with Down syndrome compared to the general population. Dev Med Child Neurol. 2016 Mar;58 (3):246-54.","DOI":"10.1111\/dmcn.12868"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Glasson EJ, Dye DE, Bittles AH. The triple challenges associated with age-related comorbidities in Down syndrome. J Intellect Disabil Res. 2014 Apr;58 (4):393-8.","DOI":"10.1111\/jir.12026"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kinnear D, Morrison J, Allan L, Henderson A, Smiley E, Cooper SA. Prevalence of physical conditions and multimorbidity in a cohort of adults with intellectual disabilities with and without Down syndrome: cross-sectional study. BMJ Open. 2018 Feb;8 (2):e018292.","DOI":"10.1136\/bmjopen-2017-018292"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bayen E, Possin KL, Chen Y, Cleret de, Langavant L, Yaffe K. Prevalence of aging, dementia, and multimorbidity in older adults with Down syndrome. JAMA Neurol. 2018 Nov;75 (11):1399-406.","DOI":"10.1001\/jamaneurol.2018.2210"},{"key":"16","unstructured":"16. Ueda K, Okamoto N, Hirayama S, Tatsumi J, Sagawa S. Daunshoukougun wo motsu seijin no kenkoukanri ni kansuru chousa: himan to metaborikkushindoromu ni chakumoku shite [Health status and health management of adults with Down syndrome: obesity and metabolic syndrome]. Nichiidenkaunseringukaishi [Jap J Genet Couns]. 2011;32 (3):101-7. Japanese."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Examination committee of criteria for &apos;obesity disease&apos; in Japan; Japan society for the study of obesity. New criteria for &apos;obesity disease&apos; in Japan. Circ J. 2002 Nov;66:987-92.","DOI":"10.1253\/circj.66.987"},{"key":"18","unstructured":"18. Japan Society for the Study of Obesity. Guidelines for the management of obesity disease 2016. Tokyo: Life Science Publishing; 2016. Chapter1-2; p. 1-17. Japanese."},{"key":"19","unstructured":"19. World Health Organization. ICD-10 Version: 2019 [Internet]. World Health Organization; 2019. [cited 2022 Feb 17]. Available from: https:\/\/icd.who.int\/browse10\/2019\/en"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lavigne J, Sharr C, Elsharkawi I, et al. Thyroid dysfunction in patients with Down syndrome: results from a multi-institutional registry study. Am J Med Genet A. 2017 Jun;173 (6):1539-45.","DOI":"10.1002\/ajmg.a.38219"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bell AJ, Bhate MS. Prevalence of overweight and obesity in Down&apos;s syndrome and other mentally handicapped adults living in the community. J Intellect Disabil Res. 1992 Aug;36:359-64.","DOI":"10.1111\/j.1365-2788.1992.tb00534.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tsou AY, Bulova P, Capone G, et al. Medical care of adults with Down syndrome: a clinical guideline. JAMA. 2020 Oct;324 (15):1543-56.","DOI":"10.1001\/jama.2020.17024"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Carf\u00ec A, Vetrano DL, Mascia D, et al. Adults with Down syndrome: a comprehensive approach to manage complexity. J Intellect Disabil Res. 2019 Jun;63 (6):624-9.","DOI":"10.1111\/jir.12588"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Prasher V, Gomez G. Natural history of thyroid function in adults with Down syndrome-10-year follow-up study. J Intellect Disabil Res. 2007 Apr;51 (4):312-7.","DOI":"10.1111\/j.1365-2788.2006.00879.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Fuller RW, Luce MW, Mertz ET. Serum uric acid in mongolism. Science. 1962 Sep;137 (3533):868-9.","DOI":"10.1126\/science.137.3533.868"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Okabe H, Mizuguchi M, Hosoya T, et al. Daunshoukougun ni gappeisuru tsufu, kounyousankesshou no kentou [Hyperuricemia and gout in Down&apos;s syndrome]. Tsufu to Kakusantaisya [Gout Nucleic Acid Metab]. 2004;28 (1):19-26. Japanese.","DOI":"10.6032\/gnam1999.28.1_19"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kashima A, Higashiyama Y, Kubota M, Kawaguchi C, Takahashi Y, Nishikubo T. Children with Down&apos;s syndrome display high rates of hyperuricaemia. Acta Paediatr. 2014 Aug;103 (8):e359-64.","DOI":"10.1111\/apa.12664"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Niegawa T, Takitani K, Takaya R, et al. Evaluation of uric acid levels, thyroid function, and anthropometric parameters in Japanese children with Down syndrome. J Clin Biochem Nutr. 2017 Sep;61 (2):146-52.","DOI":"10.3164\/jcbn.17-55"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. \u017dit\u0148anov\u00e1 I, Koryt\u00e1r P, Aruoma OI, et al. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clin Chim Acta. 2004 Mar;341 (1-2):139-46.","DOI":"10.1016\/j.cccn.2003.11.020"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Garlet TR, Parisotto EB, de Medeiros Gda S, et al. Systemic oxidative stress in children and teenagers with Down syndrome. Life Sci. 2013 Oct;93 (16):558-63.","DOI":"10.1016\/j.lfs.2013.08.017"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Carf\u00ec A, Romano A, Zaccaria G, et al. The burden of chronic disease, multimorbidity, and polypharmacy in adults with Down syndrome. Am J Med Genet A. 2020 May;182 (7):1735-43.","DOI":"10.1002\/ajmg.a.61636"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Real de, Asua D, Quero M, Moldenhauer F, Suarez C. Clinical profile and main comorbidities of Spanish adults with Down syndrome. Eur J Intern Med. 2015 Jul;26 (6):385-91.","DOI":"10.1016\/j.ejim.2015.05.003"},{"key":"33","unstructured":"33. Osako M, Takeuchi C, Mochizuki Y. Shounikihasshoushinkeikeishikkan wo yusuru kanja no shounika kara seijinshinryouka eno ikou: chiteki undoushougai wo tomonau kanja eno torikumi [Transition from pediatric to adult health care in patients with childhood-onset neurological disease: clinical practice for individuals with intellectual and physical disabilities]. Shinkeichiryou [Neurol Therap]. 2021 Mar;38 (2):112-22. Japanese."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Skotko BG, Kishnani PS, Capone GT, Down Syndrome Diagnosis Study Group. Prenatal diagnosis of Down syndrome: how best to deliver the news. Am J Med Genet A. 2009 Nov;149A (11):2361-7.","DOI":"10.1002\/ajmg.a.33082"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Skotko BG, Capone GT, Kishnani PS, Down Syndrome Diagnosis Study Group. Postnatal diagnosis of Down syndrome: synthesis of the evidence on how best to deliver the news. Pediatrics. 2009 Oct;124 (4):e751-8.","DOI":"10.1542\/peds.2009-0480"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sheets KB, Crissman BG, Feist CD, et al. Practice guidelines for communicating a prenatal or postnatal diagnosis of Down syndrome: recommendations of the national society of genetic counselors. J Genet Couns. 2011 Oct;20 (5):432-41.","DOI":"10.1007\/s10897-011-9375-8"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/2\/90_JNMS.2023_90-211\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:57:10Z","timestamp":1715317030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/2\/90_JNMS.2023_90-211\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2023_90-211","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"article-number":"JNMS.2023_90-211"}}